Phase III trial for COVID-19 vaccine, S-268019, initiated

27 December 2021

Japanese pharma major Shionogi (TYO: 4507) today announced that it has initiated a global Phase III placebo-controlled onset prevention trial in Vietnam of a prophylactic vaccine candidate (code No: S-268019) for COVID-19, caused by the novel coronavirus (SARS-CoV-2) infection.

The primary endpoint of this clinical trial is the incidence rate of COVID-19 with confirmed infection with SARS-Cov-2. In this trial, the onset prevention effect and safety of two doses of S-268019 will be assessed by comparison with placebo.

A placebo-controlled onset prevention trial is the conventional evaluation method for vaccine development. Even now, there are many countries where the supply of vaccines is inadequate. In order to contribute to effective countermeasures for global health, the company is conducting this trial. This time, Shionogi was able to initiate this clinical trial with the support of the Vietnam government, which supported this purpose and the construction of a large-scale clinical trial infrastructure in Asia.1

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK